Study details
Enrolling now
AD HOC Trial: Artificial Intelligence-Based Drug Dosing In Hepatocellular Carcinoma
University of Florida
NCT IDNCT05669339ClinicalTrials.gov data as of Apr 2026
Phase
Phase 2
Ages
18–99
Locations
1 site in FL
What this study is about
This Phase 2 study is testing Irinotecan in people with liver cancer.
Simplified from trial records by PatientMatch.
Participation Burden
What's physically and logistically required of participants.
Logistics & Travel
In-person visits
Requires travel to a study site
Physical Intervention
OralOral
How treatment is administered
Treatment Assignment
Standard assignment
Assignment is predetermined by the study protocol.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
Drug classes
irinotecan, sonidegib, sorafenib
Drug routes
oral (Oral Capsule), oral (Oral Tablet)
Endpoints
Secondary: Change in the biomarker AFP, Change in the biomarker AFP-L3, Change in the biomarker DGC, Change in the biomarker TGF-B, Objective response rate